Survey to Assess Physicians' Knowledge of Exjade Posology & Biological

See also
Status	Clinical Trial	Phase
Completed	`NCT05440487` - Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
Completed	`NCT01825512` - Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients	Phase 3
Completed	`NCT01740713` - Pharmacokinetic Study of Deferiprone in Paediatric Patients	Phase 2
Completed	`NCT02720536` - Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation	Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT05440487 - Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload

Completed

NCT01825512 - Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Phase 3

Completed

NCT01740713 - Pharmacokinetic Study of Deferiprone in Paediatric Patients

Phase 2

Completed

NCT02720536 - Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06215287
Study type	Observational
Source	Novartis
Contact
Status	Completed
Phase
Start date	January 12, 2024
Completion date	February 15, 2024

Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms